SL1ESMO International
PSY1-1Genome directed therapy for estrogen receptor positive breast cancer
PSY1-4Deep sequencing of circulating tumor DNA for personalized cancer detection and monitoring
PSY3-1Importance of fellowship training and career development planning to advance the field of medical oncology
PSY3-2How to become a clinical trialist
PSY3-4Career development in the US pharmaceutical industry
AJ-1Keynote address projects for the future
AJ-2Lung-MAP (SWOG S1400)
AOJ-1Asia as a center for global oncology drug development
AOJ-2Trends of multinational clinical trial in Asia-Oceania
AOJ-7An example of the Asian development by a pharmaceutical company
AOJ-8European views on clinical trials in Asia
EJ-2Immune checkpoint inhibitors for the treatment of cancer
EJ-3Immue checkpoint inhibitors. Clinical point of views from JSMO
EJ-4Immunotherapy for lung cancer
ISY1-1How to use EGFR-TKI in clinical practice
ISY1-2How to use afatinib in clinical practice
ISY2-2Adjuvant and neoadjuvant therapy for resectable pancreatic cancer
ISY2-3Treatment for locally advanced disease
ISY2-4S-1 based chemotherapy for metastatic pancreatic cancer
ISY2-5Current status and perspective of FOLFIRINOX for pancreatic cancer
ISY2-6Treatment for advanced and metastatic disease
ISY2-7Global perspectives on Pancreatic Cancer Treatment
ISY3-1Drug sensitivity analysis with PDX models in breast cancer
ISY3-2Molecular pathogenesis and drug development in future
ISY3-3The perspective of anti-HER2 therapy for HER2 positive breast cancer
ISY3-4Metastatic breast cancer
ISY4-4What is a useful biomarker for advanced gastric cancer (AGC)?
ISY4-5Perspectives of systemic chemotherapy for unresectable and recurrent gastric cancer ∼Cytotoxic agent ∼
ISY4-6Clinical outcomes in patients with advanced gastric cancer treated with pembrolizumab (MK-3475) in KEYNOTE-012
ISY4-7Conversion therapy using docetaxel/CDDP/S-1 (DCS) in inoperable, metastatic gastric cancer patients
ISY5-1Biologics and immunotherapy in metastatic colorectal cancer
ISY5-3The current status and a perspective on the future of colorectal cancer treatment in Japan
ISY6-3PEACE trial
ISY7-1Next generation sequencing-based cancer companion diagnostics
ISY7-4Liquid biopsies
ISY7-5Biomarkers in ovarian cancer
ISY8-2New ALK inhibitors
ISY8-3Personalized immunotherapy for advanced non-small cell lung cancer
ISY8-4ROS1 and MET Inhibitors
ISY8-5New molecular targeted agent for non-small cell lung cancer
ISY9-2WHO classification for B-cell lymphoma
ISY9-3EBV-associated lymphoproliferative disorders/lymphomas
ISY9-4Novel therapies for non-Hodgkin Lymphoma
ISY9-5Clinical trials for T/NK-cell lymphomas in Japan
ISY10-2Clinical usefulness of abiraterone acetate for Japanese patients with castration-resistant prostate cancer
ISY10-4Chemotherapy for castration resistant prostate cancer
JS1-5Circumvention of TKI resistance with HDAC inhibitors in lung cancer
JS2-2Multi-gene classifiers for prediction of recurrence in breast cancer
JS2-4Liquid biopsy could revolutionize cancer care
JS2-5Personalized targeted therapy in triple-negative breast cancer
JS3-2The clinical impact of targeting therapy in head and neck cancer
JS3-3Molecular targeting agents combined with radiation therapy for esophageal cancer
JS3-4Progress of clinical research on the combination of radiotherapy and targeted therapy for lung cancer
JS4-4Development and prospects of a new anti-cancer agent ∼ the first anti PD-1 antibody in the world ∼
JS4-5Activity for new oncology agent development in the clinical trial center
JS5-1Report of results from a survey for oncologists about the established guidelines in supportive or palliative medicine
JS5-3Early palliative care based on guideline -involvement of our palliative care team
JS6-1Effect of communication skills training program for oncologists based on patient preferences for communicating bad news
JS7-5Prognostic value of minimal residual disease response assessment in multiple myeloma
SY1-1Needs of patient-reported outcome
SY1-3Development of the US NCI patient-reported outcomes version of the common terminology criteria for adverse events
SY2-1The genomic of epithelial ovarian cancer
SY2-2Novel medical treatments for ovarian cancer; anti-angiogenesis, PARP inhibitors, and more
SY2-3Long-term prognosis for ovarian cancer based on front-line chemotherapy ∼Is it the same for each histological type?
SY2-4The property of ovarian cancer stem-like cells and the prospect for immunotherapy targeted cancer stem-like cells
SY3-1Current and future trends for the utilization of positron emission tomography (PET) for treatment strategy
SY3-4Current status and future perspective of PET/CT imaging in clinical oncology
SY4-1Recent initiatives by Japanese cancer trial groups to comply the new ethical guideline for medical research
SY5-1Development of therapeutic cancer vaccines and future prospects towards personalized medicine
SY5-2Human cancer immunopeptidomics for efficient CTL immunotherapy
SY5-7Development of a non-inflammatory adjuvant for vaccine immunotherapy against cancer
SY6-2Impact of exosomal transfer of microRNAs in cancer stem cell dorman
SY6-3MICAL3 regulates stemness of human breast cancer
SY6-4Establishment of cancer stem cell-targeting immunotherapy
SY7-3Points to be aware of in the development of antibody drugs- from our experience with mogamulizumab
SY8-1The evolving role of immunotherapy in head and neck cancer
SY8-2Induction chemotherapy in locally advanced head and neck cancer
SY8-5Molecular targeted therapy for head and neck cancer
SY9-1Cancer survivorship research and care practice
SY9-2Rainbow of KIBOU (ROK) study
SY10-1Treatment of soft tissue sarcomas
SY10-2The roles histopathological diagnosis in multidisciplinary therapy for soft tissue sarcoma
SY10-3Multicenter clinical studies for soft tissue sarcomas in Japan
SY10-6Radiotherapy for management of soft tissue sarcomas
SY11-2Medical liaison for medical practitioners in Miyagi prefecture
SY12-3Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients
SY13-2Therapeutic drug monitoring of imatinib
SY13-3Relationships between sorafenib exposure and clinical safety and efficacy
SY13-5Tamoxifen and CYP2D6 polymorphism in the treatment of hormone receptor-positive breast cancer
SY13-6Ketoconazole improved fenretinide exposures and achieved clinical responses in recurrent neuroblastoma
SY14-4When to stop chemotherapy? - Be on the same page
SY15-1The European Thoracic Oncology Platform (ETOP)
SY15-2Screening for HER2 alterations and HER2-targeted therapy in non-small cell lung cancer
SY15-3Nationwide driver mutation analysis in advanced EGFR mutation-negative non-squamous lung cancer
SY15-4ALK resistance mechanism & TKI selection
SY16-1Cancer precision medicine directed by next-generation sequencing technologies
SY16-2Precision medicine for metastatic colorectal cancer; current status and future perspectives
SY16-4Development of the new biomarker of colorectal cancer using the comprehensive molecular analyses
SY17-2Approach of medical-dental cooperation in National Cancer Center Hospital
SY17-3Oral supportive care in cancer therapy at Hokkaido University Hospital
SY17-4Practice of oral care and related issues among nurses in cancer treatment
SY17-5Oral care in palliative care settings - actual situation of oral problems and issues from the viewpoint of “total pain”
SY18-1Team approach to supportive care to control adverse effects of systemic cancer treatment
SY18-4Evidence of supportive care for cancer or therapy-related fatigue
SY19-2Genetic counseling and genetic testing for hereditary cancer syndromes
SY19-3Secondary prevention of hereditary cancer
SY19-5A challenge to establish a multidisciplinary team for the management of HBOC in Shinshu University Hospital
SY20-2Cancer rehabilitation for eating, swallowing, speech and articulation dysfunctions on the basis of the guidelines
SY20-3Exercise therapy for decreased strength and cancer-related fatigue
SY20-4The role of exercise intervention in the management of cancer cachexia
SY20-5Management of lymphedema and edema in advanced cancer
SY20-6Transdiciplinary approach for skeletal metastases in cancer patients
WS1-1Handling of anti-HER2 antibodies, trastuzumab and pertuzumab, in patients with HER2-positive breast cancer
WS1-3How to use small molecule agent for patient with human epidermal growth receptor type 2 positive breast cancer?
WS1-5How to manage bevacizumab for metastatic breast cancer?
WS3-1Development of guidelines for optimal practices in chemotherapy in oncology nursing - focusing on evidence based nursing
WS4-2Developing of a nursing intervention for promoting self-management of cancer-related fatigue in lung cancer patients
WS5-1Hazardous drugs in oncology practice
WS5-2Clinical problems on constructing the safe handling system of “hazardous drugs” in Japan
WS5-3Drug exposure from the viewpoints of pharmacists
PD1-4Pathology quality assurance in companion diagnosis
PD2-1Will molecular-targeted agents change clinical practice for advanced thyroid cancer?
PD2-2Current status and future perspectives of molecular targeting treatment for thyroid cancer
PD4-1Reactivation of HBV in patients with resolved infection during and after antitumor and/or immunosuppressive therapies
PD4-2Reactivation of hepatitis B viral infection in patients with solid tumor receiving chemotherapy
PD4-3Prophylactic measure against reactivation of hepatitis B virus in chemotherapy for gastrointestinal cancer
EL1The latest evidence of pharmacotherapies in Pancreatic Neuroendocrine Tumors (PNETs)
EL2Standards of care for Soft Tissue Sarcoma
EL4New evidence and new agent for advanced Colorectal Cancer
EL5Supportive care for patients receiving radiotherapy
EL6Prophylaxis of Febrile Neutropenia with granulocyte-colony stimulating factor
EL7Palliative medicine
EL8Screening for pain in cancer patients and the roles of oncologists
EL9New development on bone metastasis treatment
EL13Chemotherapy in older patients with cancer (Geriatric Oncology)
EL14Essence of ethical guideline of medical research for human subjects and influence of clinical research
EL20Cancer survivorship -current status in Japan
EL21Principles of endocrine therapy for breast cancer
EL22Molecular-targeted therapy for metastatic renal cell carcinoma
EL24Immune-checkpoint Inhibitor in clinical practice
EL30Helicobacter pylori Oncoprotein CagA and gastric cancer
EL31Immunopathology of cancer stem cells
ISS1-1-1PF-05212384 + irinotecan Phase II study in metastatic colorectal cancer (mCRC)
ISS1-1-2The significance of EGFR pathway mutations for the efficacy of bevacizumab in metastatic colorectal cancer
ISS1-1-3Safety and efficacy on TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer (mCRC)
ISS1-2-1Updates on PFS and safety results of a Phase I / II study (AF-001JP) of alectinib in ALK-rearranged advanced NSCLC
ISS1-2-4An activating ALK gene mutation in ALK IHC-positive/FISH-negative non-small cell lung cancer
ISS1-3-2Prognostic index model for overall survival in advanced unresectable pancreatic cancer from GEST study
ISS1-3-4Final phase II results for sunitinib (SU) in Japanese pts with well-differentiated pancreatic neuroendocrine tumor (NET)
ISS2-1-55-weekly S-1 plus cisplatin combined with trastuzumab for HER2-positive gastric cancer (WJOG7212G)
ISS2-2-1Nationwide genomic screening network for the development of targeted therapies in NSCLC (LC-SCRUM-Japan)
ISS2-2-5ADAM9-associated microRNA suppression promotes lung cancer progression
ISS3-1-2Age-related disparity in early prognosis of patients with triple-negative breast cancer
ISS3-1-4Use of MR parameters chosen from PET to predict response to neoadjuvant chemotherapy in breast cancer; parallel PET/MRI
ISS3-1-5Immune signatures may differ between early operable breast cancer and metastatic breast cancer patients
ISS3-1-6Changes in biologic features between primary and recurrent breast cancers
ISS3-2-3Clinical verification of sensitivity to pre-operative chemotherapy androgen in case of receptor expressing positive TNBC
ISS3-2-4Predictions of pathological response after preoperative chemotherapy plus trastuzumab in HER2-positive breast cancer
O1-3-1Comparison between NAC-S and CRT in overall survival for patients with esophageal squamous cell carcinoma (JCOG1406-A)
O1-3-2Phase II study of chemoradiotherapy with docetaxel for elderly patients with stage II / III esophageal carcinoma
O1-4-1Significance of hypersensitivity reactions in the outpatient infusion unit
O1-4-5Preventive strategy of reactivation of hepatitis B virus at Kansai Medical University Hospital
O1-5-1Short-term low-volume hydration in cisplatin-based chemotherapy
O1-5-3Challenge and current status of night outpatient chemotherapy in our institution
O1-5-4The efficacy of peripherally inserted central catheter in cancer chemotherapy
O1-6-3A clinical prediction model for infusion reaction to rituximab
O1-6-5Mechanisms of decreasing oxaliplatin-related vascular pain by coadministration of 5% glucose solution and dexamethasone
O1-7-1Venous thromboembolism in hospitalized cancer patients receiving chemotherapy in Japan
O1-7-2Electroacupuncture treatment in morphine tolerance rat model with metastatic bone pain
O1-7-4Effective supportive care for patients with physiological changes in various skin regions induced by EGFR inhibitors
O1-7-5The efficacy of prophylactic G-CSF for FOLFIRINOX
O1-8-3Phase II study of erlotinib + onartuzumab as first-line treatment for patients with MET-positive and EGFR-mutant NSCLC
O1-9-1ARCHER 1050
O1-9-2Phase I / II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations
O1-9-6A prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer
O1-10-1Comparison of various EGFR tyrosine kinase inhibitors (TKIs) for tumors with exon 18 mutations of the EGFR gene
O1-10-2Combined analysis of two Phase II studies evaluating first-line erlotinib in NSCLC with EGFR mutation
O1-10-3Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
O1-10-4Clinicopathological analysis between exon 19 deletion and L858R in EGFR-mutant completely resected lung adenocarcinoma
O1-10-5Effect of genetic polymorphisms on erlotinib pharmacokinetics and toxicity in patients with non-small-cell lung cancer
O1-11-1Sarcopenia and adipopenia are independent prognostic factors in patients with acute myeloid leukemia
O1-11-2The efficacy of gemtuzumab ozogamicin in patients with acute leukemia
O1-11-3A phase I b study of panobinostat and 5-azacitidine in Japanese patients with MDS, CMML, or AML
O1-12-1Efficacy and safety of dose-adjusted lenalidomide therapy in relapsed/refractory myeloma patients with renal impairment
O1-12-2Efficacy and safety of denosumab for multiple myeloma
O1-12-5Central nervous system relapse in diffuse large B-cell lymphoma
O1-13-1Clinical feature in adolescent and young adult with suspected carcinoma of unknown primary
O1-13-2Clinical characteristics and outcome of ovarian, fallopian tube and peritoneal-like cancer in cancer of unknown primary
O1-13-3Clinical characteristics of cancer of unknown primary cancer with poorly differentiated carcinoma and adenocarcinoma
O1-13-4Integrative algorithm to determine the metastatic carcinoma tissue of origin using next generation sequencing (NGS)
O1-13-6Introduction of clinical sequence using a comprehensive cancer gene panel (OncoPrime) to daily clinical practice
O1-14-6Study of outpatient oral continued follow-up system in Regorafenib patients treated for colorectal cancer
O1-15-1Management and treatment of soft tissue sarcoma patients by medical oncologists in multidisciplinary center
O1-15-3Raising awareness of health care providers in Nara for patients' care through multidisciplinary workshop “MAHOLOBA”
O1-15-6Improvement in the awareness of palliative care nursing using STAS-J in an acute care hospital
O1-16-6The role of palliative care unit co-operating with regional medical systems to provide reliable patient care
O1-17-3Safety and efficacy of modified FOLFIRINOX in patients with metastatic pancreatic cancer
O1-17-4Updated analysis of weekly nab-Paclitaxel (P)+ Gemcitabine (G) with metastatic pancreatic cancer (MPC)
O1-17-5S-1/oxaliplatin/irinotecan (SOXIRI) for advanced unresectable pancreatic cancer
O1-18-2Development of online education program for certified chemotherapy nurses regarding molecular targeted therapy
O1-19-3Pattern of metastasis related to clinicopathological features in curatively resected head and neck cancer
O1-19-4Biomarker and gene profiling analyses in acute myeloid leukemia during treatment with Hedgehog signaling inhibitor
O1-19-5A new approach to collecting biobank and bioinformatics data at Kyoto University Cancer Center
O1-20-5A Clinical study on activity of NAMPT and SIRT1 gene expression in neutropenia with cancer chemotherapy
O2-1-2Locally advanced head and neck squamous cell carcinomas treated with TPF(docetaxel, cisplatin, 5-FU)induction chemotherapy
O2-2-5Clinical verification of a molecular mechanism of antitumor effect of eribulin chemotherapy
O2-3-2LURET study
O2-3-5Bevacizumab beyond disease progression in advanced non-squamous NSCLC (WJOG 5910L)
O2-4-4Phase II study of carboplatin/pemetrexed/bevacizumab followed by bev/erlotinib maintenance for non-squamous NSCLC with WT EGFR
O2-4-5Phase II study of carboplatin plus weekly nab-paclitaxel in elderly patients with NSCLC
O2-5-1Ultrasound-guided Port-A-Cath implantation-personal experience of 586 cases
O2-5-5Retrospective study on complications of upper arm central venous access ports
O2-6-1Low emetic chemotherapy–induced nausea and vomiting
O2-6-2A randomized phase II trial of triplet or doublet antiemetic therapy in lung cancer patients receiving MEC (NLCTG1002)
O2-6-4Analysis of efficacy and safety of aprepitant in R-CHOP or R-TCOP chemotherapy for NHL
O2-7-1Garenoxacin (GRNX) for secondary prophylaxis against febrile neutropenia (FN) in chemotherapies for advanced lung cancer
O2-7-4Association between febrile neutropenia and use of G-CSF in chemotherapy of extensive-disease small-cell lung cancer
O2-7-5A retrospective study of D-index in acute myeloid leukemia patients undergoing induction chemotherapy
O2-7-6Fever after cancer chemotherapy is affected by drug fever on post-treatment days 3-4
O2-8-1Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC)
O2-8-5Randomized controlled trial of epirubicin and miriplatin using together with TACE for hepatocellular carcinoma
O2-8-6Genomic instability in hepatitis B virus-induced hepatoma and its clinical implication
O2-9-1The anti-cancer mechanism of histone deacetylase inhibitor in human pancreatic carcinoma
O2-9-2Modified FOLFIRINOX in pancreatic cancer patients with double variant type of UGT1A1 polymorphism
O2-9-4Bioactive insulin-like growth factors as a possible molecular target for non-islet cell tumor hypoglycemia
O2-10-1Pain and quality of life between smoking and nonsmoking patients with advanced lung cancer
O2-10-2Predictive values of activity of daily livings score for the identification of worse performance status
O2-10-4Risk factors for predicting severe neutropenia induced by pemetrexed plus carboplatin therapy in patients with NSCLC
O2-11-2Efficacy and safety in genetic and clinical subgroups
O2-11-3Influence of rituximab(R) -fludarabine(F) and R-bendamustine(B) therapy on the immune system in relapsed lymphoma
O2-11-4Beta-2 microglobulin as a significant prognostic factor and a new risk model for diffuse large B-Cell lymphoma
O2-12-3Safety and efficacy of R-THP-COP for over 80 years elderly patients with diffuse large B-cell lymphoma
O2-12-5G-CSF after the first cycle of R-CHOP or mini R-CHOP ∼ Who needs it as a primary prophylaxis?
O3-1-3Retrospective analysis between PD-L1 expression and prognosis for stage III non-small cell lung cancer patients
O3-1-5Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
O3-2-1Long-term results of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer
O3-2-4Hematologic toxicity of amrubicin monotherapy in recurrent small-cell lung cancer
O3-3-2A phase II study of gemcitabine plus carboplatin as adjuvant chemotherapy in patients with resected NSCLC
O3-3-4Stereotactic body radiotherapy for pulmonary oligometastases with emphasis on the difference in oligometastatic state
O3-4-4Multidisciplinary treatment in patients with leptomeningeal metastasis from gastric cancer
O3-5-4Establishment of a terminal prognosis prediction model by applying time series analysis to real-world data
O3-6-1Trifluridine-tipiracil for multidrug-resistant advanced colorectal cancer
O3-6-3Self-reported adherence with TAS-102
O3-6-5Both regorafenib and TAS-102 give metastatic colorectal cancer patients survival benefit with different toxicity profile
O3-6-6Gastrointestinal perforation and fistula formation in colorectal cancer patients during regorafenib treatment
O3-7-3A prospective study of S-1 + Irinotecan plus bevacizumab as second-line therapy in metastatic colorectal cancer (KSCC1102)
O3-9-2Characterization of tumor-infiltrating CD8+ T lymphocytes in malignant lymphoma
O3-9-4Gemcitabine synergistically enhances anti-tumor effects of recombinant immunogen-based cancer immunotherapy
O3-10-2A new management model of oral outpatient chemotherapy featured by concerted interventions by physicians and pharmacists
O3-11-1Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
O3-11-2Dosing schedules and outcomes in patients with first-line sunitinib for advanced renal cell carcinoma
O3-12-1Pharmacokinetic advantage of hipec using minimal extracorporeal circuit in patients with peritoneal carcinomatosis
O3-12-6Associations between early end of life discussion and care received near death in advanced ovarian cancer patiens
O3-13-1Characterization of LASEP1 as a new serological and prognostic biomarker and a therapeutic target for lung cancer
O3-13-3Epithelial to mesenchymal transition by TGF-beta induced cancer stem-like properties in primary colorectal cancer
O3-14-3Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid
O3-14-5Management of bone metastasis in the patients achieved 10-year survival with recurrence from breast cancer
O3-15-4Development of nomograms for predicting survival in advanced gastric cancer
O3-13-6Molecular characterization of BRCA1 with clinico-pathological features among the breast cancer patients of Eastern India
O3-15-5What is the best fluoropyrimidine + platinum for advanced gastric cancer (AGC) ? -the inspect of early tumor shrinkage-
O3-15-6Prognostic factors in elderly patients with advanced gastric cancer
O3-16-1Treatment results of trabectedin (T) in patients (pts) with myxoid-round cell liposarcoma (MRCL)
O3-16-2The relationship between time to treatment, disease stage and prognosis in head and neck rhabdomyosarcoma in adults
O3-16-3Peripheral neuropathy of VAC therapy for adult rhabdomyosarcoma
O3-16-6Clinical outcomes in 21 patients with gastrointestinal stromal tumor(GIST)treated in phase I trials
P1-1-4Prognosis of non-small cell lung cancer patients with brain metastasis
P1-1-6Seventy-four lung cancer patients under 50 years old
P1-1-20Systemic chemotherapy for pulmonary pleomorphic carcinoma
P1-1-24A novel approach to overcome non-small-cell lung cancer
P1-1-25TP53 mutation signature can predict prognosis of early lung adenocarcinoma
P1-1-54Definitive thoraco-systemic therapy plus brain local therapy for ED-SCLC with metastasis only to the brain
P1-1-70Clinical significance of SUVmax on PET/CT in c-T1a (less than 20 mm) non-small cell lung cancer
P1-1-72How to obtain the raw sample of non-small cell lung cancer for mutation screening in a tertialy hospital
P1-1-73Safety and yield of real time ultrasound-assisted cutting needle biopsy performed by medical oncologist
P1-1-80Role of community based integrated care ward in the lung cancer practice-revision of medical treatment fees for 2014
P1-2-3Analysis of gemcitabine therapy for relapsed or refractory malignant lymphoma in one institute
P1-2-4DeVIC chemotherapy is effective for patients with refractory or relapsed diffuse large B-cell lymphoma
P1-2-7Retrospective analysis of primary breast diffuse large B-cell lymphoma cases in our institute
P1-2-10Clinicopathological features and complications of gastrointestinal non-Hodgkin's lymphoma -a single institute analysis
P1-2-11Bendamustine therapy for relapsed or refractory low grade B cell lymphoma and mantle cell lymphoma
P1-2-12Efficacy of 90Y-ibritumomab tiuxetan treatment for relapsed and refractory low-grade B-cell and mantle cell lymphoma
P1-2-13A retrospective analysis about Stenotrophomas maltophiria sepsis in patients with hematological malignancy
P1-2-16Reversible posterior leukoencephalopathy syndrome during R-ICE therapy for malignant lymphoma
P1-2-18Efficacy and safety of transarterial chemoembolization using drug eluting beads for hepatocellular carcinoma
P1-2-20Embolization therapy with microspheres for liver metastases
P1-2-51Serious bronchiolitis obliterans organizing pneumonia associated with azacitidine in two MDS patients
P1-2-59A possible link between ITP developed in a patient with relapsed multiple myeloma and maintenance thalidomide
P1-2-61Therapeutic approach for primary plasma cell leukemia
P1-2-66Bortezomib and dexamethasone for multiple myeloma
P1-2-67The clinical features of patients with advanced HCC treated with sorafenib who experienced long-term survival
P1-2-70Effective management of male primary hepatic choriocarcinoma
P1-3-3Cancer of unknown primary site with pathological characteristic of the breast cancer
P1-3-4Amrubicin therapy for platinum-refractory extrapulmonary neuroendocrine carcinoma
P1-3-54A case with cancer of unknown primary diagnosed pathologically retroperitoneal squamous cell carcinoma
P1-3-55Effectiveness of detecting the primary lesion of CUP using FDG-PET/CT
P1-3-59An autopsy case of primary cervical neuroendcrine carcinoma proceeded liver metastasis
P1-4-3Lymphangiography for refractory postoperative chylothorax
P1-4-8A case of cancer of the ascending colon perforated by barium enema examination
P1-4-51Concordance of ALK rearrangement patterns between CTCs and tumour in non-small cell lung cancer (NSCLC)
P1-4-52Identification, functional study and clinical application of novel ALK fusion genes
P1-4-53Re-biopsy of twelve non small cell lung cancer (NSCLC) cases
P1-5-3The association between time to recurrence after curative surgery and prognosis in stage III colorectal cancer
P1-5-9Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy
P1-5-10An autopsy case of AFP producing carcinoma of the rectum with multiple liver metastases treated by cetuximab + mFOLFOX6
P1-5-15A retrospective analysis of 5-fluorouracil plus cisplatin in metastatic or recurrent esophageal squamous cell carcinoma
P1-5-16Exploratory analysis of prognostic subset in esophageal cancer patients previously treated with FU, Pt, taxane therapy
P1-5-18Re-introduction of taxane for patients with esophageal squamous cell carcinoma refractory to 5-FU, CDDP, and a taxane
P1-5-19Study of the gene expression of esophageal squamous cell carcinoma-associated novel candidate genes
P1-5-23Efficacy and feasibility of preoperative chemotherapy for elderly patients with stage II / III esophageal cancer
P1-5-55A case of SIADH following cisplatin and 5-fluorouracil chemotherapy in a patient with esophageal cancer
P1-5-57DCF therapy led to a curative operation for a patient with esophageal carcinoma after the failure of CF therapy
P1-5-60Chemotherapy after stent placement for unresectable colorectal cancer stenosis
P1-5-61Characterization of serum HER2 extracellular domain (ECD) level in patients with metastatic colorectal cancer
P1-5-77A case of rectal cancer with bilateral pulmonary metastasis successfully treated with neoadjuvant chemotherapy and SBRT
P1-5-78Successful treatment with “re-switching” of regorafenib and cetuximab for mCRC patient with liver metastases
P1-5-81A recurrent colorectal cancer case with 5-FU-induced hyperammonemic encephalopathy, continuously receiving a reduced dose
P1-6-14Oral supportive care for cancer patients receiving chemotherapy
P1-6-52The similar efficacy and safety of lenograstim and filgrastim biosimilar for Japanese with primary non-Hodgkin-lymphoma
P1-6-6Study risk assessment of JCOG clinical trials using the EORTC study risk calculator
P1-7-13Recombinant soluble thrombomodulin for disseminated intravascular coagulation patients with hematological malignancy
P1-7-4Influence of construction work on aspergillus infection for patients with hematological malignancies
P1-7-5Peripherally inserted central catheters performed at bedsides in cancer patients
P1-7-52A single-center retrospective study of a short hydration schedule for cisplatin-based chemotherapy
P1-7-55Evaluation of the G8 screening tools for fraility in older patients with cancer
P1-7-57Cooperation between hospital and health insurance pharmacy based on results of questionnaire survey for cancer patients
P1-7-62Training program of cancer professionals and regional contribution in Sanin area
P1-8-1Retrospective study of FOLFIRINOX in early intolerable patients with unresectable pancreatic cancer in our institution
P1-8-2FOLFIRINOX with modified regimen therapy for advanced pancreatic cancer in Okayama university hospital
P1-8-8FOLFIRINOX for locally advanced or metastatic pancreatic cancer
P1-8-9Retrospective research for efficacy and safety of modified FOLFIRINOX as 1st line therapy for advanced pancreatic cancer
P1-8-11Retrospective analysis of FOLFIRINOX for unresectable pancreatic cancer
P1-8-14FOLFIRINOX for locally advanced and metastatic pancreatic ductal adenocarcinoma
P1-8-15Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis for the standard therapeutic dose
P1-8-24A case of pancreatic cancer in a patient who suffered CPA during TC therapy and was diagnosed at autopsy with AMI
P1-8-51Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma
P1-8-56A retrospective analysis of the efficacy and safety of everolimus in patients with unresectable tumor
P1-8-61SIRT-Y90 followed by gemcitabine plus cisplatin for Intra-hepatic cholangiocarcinoma
P1-8-65Therapeutic strategy for resectable pancreatic cancer patients with thromboembolic risks
P1-8-68Retroperitoneal emphysema and interstitial pneumonitis during FOLFIRINOX in a patient with pancreatic cancer
P1-9-1Proteomics profiling of epigenetic proteins during acinar morphogenesis to identify prostate cancer prognostic markers
P1-9-56Anti-leukemic mechanisms of novel FTY720 analogue-a crucial role of mitochondrial stress in apoptosis and autophagy
P1-9-57Mechanism study of structural analogue of sphingosine mediated anti-proliferative and autophagic activities in HRPC
P1-9-61Antitumor activity of fenugreek (Trigonella foenum graecum L.) powder seeds in vivo
P2-1-1A retrospective study comparing pemetrexed with taxanes as front-line cytotoxic chemotherapy for lung adenocarcinoma
P2-1-3Clinical features of patients with advanced non-squamous non-small cell lung cancer treated with long-term pemetrexed
P2-1-4Comparison of platinum rechallenge and docetaxel in non-small cell lung cancer previously treated with chemoradiotherapy
P2-1-6Concurrent chemoradiotherapy with cisplatin/vinorelbine and cisplatin/docetaxel in locally advanced stage III NSCLC
P2-1-10Prospective study of UGT1A1*27 polymorphism for irinotecan therapy
P2-1-12Retrospective study of chemotherapy for non-small cell lung cancer, complicated pleural effusion
P2-1-17Clinical outcomes of nab-paclitaxel for advanced or relapsed non-small cell lung cancer patients
P2-1-19Nanoparticle albumin-bound paclitaxel as 2nd line chemotherapy for small cell lung cancer with interstitial lung disease
P2-1-22A multicenter phase II study of S-1 plus bevacizumab in patients with previously treated non-squamous NSCLC
P2-1-23Final survival analysis of the phase II Study of weekly paclitaxel plus bevacizumab in previously treated non-Sq NSCLC
P2-1-26Adverse effect of Bevacizumab; comparison between lung cancer versus colon cancer
P2-1-54Primary malignant melanoma of the esophagus successfully treated with nivolumab
P2-1-55Immune-related response kinetics in patient with melanoma receiving nivolumab, programmed cell death 1 (PD-1) inhibitor
P2-1-56Stereotactic body radiation therapy for lung cancer with paraneoplastic limbic encephalitis
P2-1-57De-novo EGFR mutation and MET amplification in NSCLC with crizotinib response; a case against one-gene/one-drug paradigm
P2-1-58A case of hemodialysis patient with small cell lung cancer under concurrent chemoradiotherapy with CBDCA plus Etoposide
P2-1-76Radiation recall pericarditis(RRP)induced by amrubicine
P2-2-2The safety and efficacy profiling of T-DM1 treatments of metastatic breast cancer patients
P2-2-7Breast cancer case with multiple brain metastases responding to T-DM1
P2-2-10Dose escalation of eribulin + cisplatin as induction chemotherapy in chemo-refractory triple negative breast cancer
P2-2-22Virtual endoscopic mode of 3D-CT will navigate video-assisted breast surgery
P2-2-23Effectiveness of intraoperative histologic assessment of surgical margins for breast-conserving surgery
P2-2-52Urine NTx changes predict the survaival in breast cancer patients with bone metastasis receiving denosumab
P2-2-55Study of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer
P2-2-56Analysis of five days administration of TS-1 followed by a two-day rest in patients with metastatic breast cancer
P2-2-72An aromatase inhibitor (AI) has led to long-term remission in a gastric cancer case with bilateral breast cancers
P2-3-2Safety profile of modified FOLFIRINOX
P2-4-5CCL5 promotes vascular endothelial growth factor-dependent angiogenesis in human osteosarcoma
P2-4-53EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition
P2-5-9Application of regorafenib to metastatic colorectal cancer patients in clinical practice; a retrospective study
P2-5-20Dose-escalation of REgorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study
P2-5-21Phase II study of Ccr-based dose-control of S-1 in 1st line SOX + bevacizumab regimen for advanced colorectal cancer
P2-5-22LUME-Colon 1
P2-5-26Comparison of the effects of anti-EGFR and anti-VEGF antibody as first-line treatment for metastatic colorectal cancer
P2-5-53Skin disorders caused by molecular targeted therapies in colon cancer patient
P2-5-55Importance to clarify germline hMLH1 K618A missense mutation for clinical surveillance and genetic counseling
P2-5-78Antihypertensive therapy of bevacizumab-induced hypertension
P2-6-51The actual condition of chemotherapy for outpatients with poor performance status
P2-6-57Effect of team medical palliative care on chemotherapy for outpatients
P2-8-2Using all available agents may be useful as 2nd or higher line CT for pts with ARGC after the failure of S-1 based CT
P2-8-10Development of dosing recommendation of S-1 for patients with renal dysfunction by prospective pharmacokinetic study
P2-8-12The peripheral neuropathy with paclitaxel after oxaliplatin for the patients with gastric cancer
P2-8-13A retrospective study of early toxicity of weekly paclitaxel as second line chemotherapy for advanced gastric cancer
P2-8-15The validity of 5FU-Levofolinate regimen as an alternative for advanced gastric cancer with mild renal failure
P2-8-20Salvage line CPT-11 after failure of fluoropyrimidine and paclitaxel-based chemotherapy in advanced gastric cancer
P2-8-25Prognostic factors in patients with advanced gastric cancer treated with cisplatin plus fluoropyrimidine
P2-8-51Three cases of the HER2-positive advanced gastric cancer with elevated serum alpha-fetoprotein (AFP)
P2-8-63A case of gastric cancer that could continue chemotherapy with UFT after developing severe S-1 drug eruption
P2-8-664 cases of advanced gastric cardia adenocarcinoma treated with chemoradiotherapy
P2-8-678-year maintenance of Stage IV gastric cancer by repeated surgery, radiation therapy and metronomic chemotherapy
P2-8-68Endometrial signet ring cell metastasis from advanced gastric cancer
P2-8-69A case of unresectable Stage IV HER2-positive advanced gastric cancer treated by using trastuzumab combined with SOX
P2-9-1Risk and epidemiology of cancer related ischemic stroke in head and neck cancer patients
P2-9-3Combined modality treatment of Nasopharyngeal cancer with IMRT& Concurrent/Adjuvant Chemotherapy-First report from Nepal
P2-9-9Concurrent CBDCA plus radiotherapy for locally advanced head and neck cancer patients inappropriate for use of CDDP
P2-9-10A study of chemoradiotherapy with high dose cisplatin for postoperative high-risk squamous cell carcinoma of oral cavity
P2-9-11Retrospective analysis of emergency hospital admission due to chemoradiotherapy for head and neck cancer patients
P2-9-52Retrospective analysis of anti-allergy prophylaxis for infusion reactions of cetuximab in head and neck cancer patients
P2-9-58Tolerability and problems of sorafenib treatment in differentiated thyroid cancer
P3-1-1Clinical outcomes of 1st-line gefitinib for patients with advanced NSCLC harboring EGFR mutations and poor PS
P3-1-15Second-generation EGFR-TKI (afatinib) rechallenge to overcome acquired resistance to first-generation EGFR-TKIs
P3-1-17Management of toxicities and dose reduction/interruption of afatinib for EGFR mutated non-small cell lung cancer
P3-1-21A case of treatment with afatinib + paclitaxel combination after PD treatment with afatinib in a patient with NSCLC
P3-1-23A retrospective analysis of tolerability in EGFR-mutated NSCLC patients who received afatinib
P3-1-56Outcome of two patients harboring EML4-ALK fusion gene with brain metastasis treated with crizotinib
P3-1-61Enhancement of the anticoagulant effect of warfarin by gefitnib administration
P3-1-63Neutrophil-to-lymphocyte ratio and treatment outcome in NSCLC patients received EGFR-TKI as first or second-line therapy
P3-1-64Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma
P3-1-70Squamous cell histological transformation beyond EGFR TKI treatment against EGFR-mutant lung adenocarcinoma
P3-1-71A case with small-cell transformation after treatment with EGFR tyrosine kinase inhibitor for lung adenocarcinoma
P3-1-74Fourteen cases of ADL and cognitive function during high-dose methotrexate treatment for malignant primary CNS lymphoma
P3-2-1The relationship among physical activity, QOL and self-efficacy of perioperative patients with gastric cancer
P3-2-55Team medical care for oral anticancer agents induced adverse events
P3-2-58Construction of the system of treatment for deep venous thrombosis with malignant tumor in Anjo Kosei Hospital
P3-2-61Regorafenib team
P3-3-2Potential of the 5-fluorouracil dose-escalation method for dihydropyrimidine dehydrogenase-deficient patients
P3-3-3Effect of renal function on continuation of S-1 adjuvant chemotherapy in gastric cancer patients
P3-3-54Thiotepa for autologous hematopoietic stem cell transplantation for solid tumors
P3-4-3Fertility-preservation therapies for cancer patients
P3-5-1Efficacy and safety of pertuzumab for HER2 positive metastatic breast cancer
P3-5-13Clinical outcomes in different lines for advanced and metastatic breast cancer patients receiving fulvestrant
P3-5-20PF-05280014, a potential biosimilar to trastuzumab
P3-5-23Impact of pretreatment anemia on outcomes of Chinese women with breast cancer receiving neoadjuvant chemotherapy
P3-5-26Aloe-emodin enhances cytotoxicity of tamoxifen through suppressing Ras/ERK and PI3K/mTOR pathways in breast cancer cells
P3-5-56Clinical outcome for HR + /HER2- stage IV breast cancer patients
P3-5-58The retrospective cohort study of hormonal therapy resistant ER-positive breast cancer
P3-5-60Examination about febrile neutropenia in patient performed FEC with breast cancer
P3-5-67Anti-HER2 therapy for HER2-positive metastatic breast cancer
P3-5-71Response rate and treatment periods of vinorelbine ± trastuzumab for metastatic and recurrent breast cancers
P3-5-72A cases of pertuzumab + trastuzumab + docetaxel was effective for inflammatory breast cancer with HER2-positive
P3-5-74Two cases of clinical tumor lysis syndrome following lapatinib in HER2 positive breast cancer
P3-6-3Significance of metastasectomy for urothelial carcinoma
P3-6-4Efficacy and safety of etoposide in patients with platinum-pretreated metastatic or recurrent urothelial cancer
P3-6-5An investigation about the efficacy of measuring serum CA 19-9 in patients with advanced urothelial carcinoma
P3-6-6Retrospective analysis of chemotherapy with S-1 and cisplatin for advanced urachal carcinoma
P3-6-7A retrospective analysis of cisplatin and S-1 chemotherapy for 5 patients with advanced / recurrent urachal carcinoma
P3-6-8Treatment of metastatic renal cell carcinoma with low-dose interleukin-2
P3-6-11Initial evaluation of the clinical efficacy and safety of enzalutamide in castration-resistant prostate cancer
P3-6-12Short-term outcome of enzalutamide in Japanese patients with castration-resistant prostate cancer
P3-7-2A retrospective investigation of low dose oxycodone by continuous subcutaneous infusion in terminal cancer patients
P3-7-3Retrospective study of safety and efficacy of oxycodone for oxycodone-naive patients with or without hepatic dysfunction
P3-7-7Retrospective study on the safety and efficacy of CART for patients with malignant ascites who received chemotherapy
P3-7-56Relief of severe cancer pain by subarachnoid analgesia in a young patient with peritonitis carcinomatosa of gastric cancer, allowing him to share the birth of his first daughter
P3-7-60Perspectives of good death among Filipino cancer patients, family members and health care providers in Davao city
P3-7-61Post mastectomy pain among breast cancer patients at Southern Philippines Medical Center
P3-7-63Palliative care in Egypt
P3-8-1Efficacy and safety of gemcitabine containing regimen for refractory and relapsed non-Hodgkin lymphoma
P3-8-2The efficacy and safety of gemcitabine, dexamethasone, and cisplatine (GDP) therapy for relapsed/refractory lymphoma
P3-8-3Treatment outcome of GDP regimen for patients with refractory or relapsed adult T-cell leukemia-lymphoma
P3-8-6A review of six cases of aggressive NK cell leukemia in our institute
P3-8-7Profile of aplastic anemia
P3-8-8Chemotherapy for malignant lymphoma patients. Oral care is necessary?
P3-8-18Questionnaire survey analysis for awareness of multidisciplinary medical staff in Nara for exposure to anti-cancer drugs
P3-8-52An autopsy case of duplicate malignancy with acute myeloid leukemia and gastric cancer
P3-8-55Effect of dasatinib on relapse Ph positive lymphoblastic lymphoma after stem cell transplantation
P3-8-62A case of acquired hemophilia A and B as paraneoplastic syndromes of breast cancer
P3-8-63Case of small intestinal double hit lymphoma forming cutaneous fistula between intestinal lumen in Western patients
P3-9-2Development of dedifferentiated liposarcoma during JAK inhibitor treatment in a rheumatoid arthritis patient
P3-9-4A case of angiosarcoma partially effective to pazopanib after number of cycles of docetaxel treatments
P3-9-5Primary cardiac angiosarcoma diagnosed by examinations for the symptom of anterior chest oppression
P3-9-7A patient with primary right iliac carcinosarcoma who improved with chemo-radiation
P3-9-10Case report
P3-9-12A case report of cardiac intimal sarcoma treated with pazopanib and dexamethasone (DEX)
P3-9-52Treatment of VAC chemotherapy to adult with rhabdomyosarcoma
P3-9-64Hadrontherapy by carbon ions, an innovative approach to treat chondrosarcomas